Skip to main content

OrbiMed Advisors LLC's Form 4 filing

BlossomHill Therapeutics, Inc. (BLSM) · filed Aug 12, 2026

Accession no.
0000947871-26-000784
Filed
Aug 12, 2026, 4:43 PM ET
Trade date
Aug 10, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market purchases total $10.0M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
OrbiMed Advisors LLCCIK 0001055951Director
OrbiMed Capital GP VIII LLCCIK 0001845804Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 10, 2026Common StockCConversionAcquired+1,039,996––1,039,996Indirect
Aug 10, 2026Common StockCConversionAcquired+1,049,283––2,089,279Indirect
Aug 10, 2026Common StockPPurchaseAcquired+625,000$16.00+$10,000,0002,714,279Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 10, 2026Common StockCConversionDisposed−1,039,996$0.00$00Indirect
Aug 10, 2026Common StockCConversionDisposed−1,049,283$0.00$00Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)